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Summary
BACKGROUND: Simple tools for risk stratification of pa-
tients with acute heart failure (AHF) are an unmet clinical
need, particularly regarding long-term mortality.
METHODS: We prospectively enrolled 610 consecutive
patients presenting to the emergency department with AHF.
The diagnosis of AHF was adjudicated by two independent
cardiologists. The classification and regression tree
(CART) analysis was used to develop a simple risk al-
gorithm. This was internally validated by cross-validation.
RESULTS: One-year follow-up was complete in all pa-
tients (100%). A total of 201 patients (33%) died within
360 days. The CART analysis identified blood urea nitro-
gen (BUN) and age as the best single predictors of 1-year
mortality and patients were categorised to three risk
groups: high risk group (BUN >27.5 mg/dl and age >86
years), intermediate risk group (BUN >27.5 mg/dl and age
≤ 86 years) and low risk group (BUN ≤ 27.5 mg/dl). The
Kaplan-Meier curves showed a significant increase in mor-
tality in the high risk group compared with the lower risk
groups (log-rank test p <0.001). The hazard ratio regarding
1-year mortality between patients identified as low and
high risk was 2.0 (95% confidence interval, 1.7–2.4), with
statistically significant differences between all risk groups
(p <0.001). The likelihood-based 95%-confidence set for
the age- and the urea-threshold is contained in the rectan-
gular set defined by 25 mg/dl ≤ urea threshold ≤30.6 mg/dl
and 76 years ≤ age threshold ≤96 years.
CONCLUSION: These results suggest that AHF patients at
low, intermediate and high risk for death within 360 days
can be easily identified using patient’s demographics and
laboratory data obtained at presentation. Application of this
simple risk stratification algorithm may help to improve the
management of these patients.
Keywords: acute heart failure; risk stratification; 1-year
mortality
Introduction
Heart failure (HF) is a major public health problem, espe-
cially in industrialised nations. Approximately fifteen mil-
lion Europeans and North Americans suffer from HF and
over one and half million new cases of HF are diagnosed
each year [1, 2].
In addition, in patients older than 65 years HF is the leading
cause of hospitalisation. HF is associated with high mor-
bidity and mortality [3]. In contrast to chronic heart failure,
risk stratification is poorly defined in acute heart failure
(AHF) patients, particularly regarding long-term mortality
[4–7].
Early risk stratification in AHF patients may help clinicians
to individualise treatment and manage decisions [8]. For
example, many AHF patients identified to be at low risk
could be discharged early from the emergency department
(ED) and obtain outpatient treatment. On the other hand,
high risk patients might benefit from a rapid transfer to the
intensive care unit with more effective treatment options.
However, the prognostic performance of single variables is
weak in AHF [9].
Several prior studies have defined risk stratification models
for in-hospital mortality in patients hospitalised with AHF
[10–12]. Recently, a simple risk stratification scheme for
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the prediction of in-hospital mortality based on classific-
ation and regression tree (CART) analysis was developed
by the Acute Decompensated Heart Failure National Re-
gistry (ADHERE) [10]. It was unknown whether a similar
approach would allow the prediction of mortality beyond
the in-hospital period.
Therefore, the purpose of this study was to examine the
utility of a simple algorithm in unselected AHF patients re-
garding 1-year mortality.
Methods
Setting and study population
The study population consisted of consecutive patients
with AHF presenting to the ED, University Hospital of
Basel (Switzerland), during two periods: May 2001 to
April 2002 and April 2006 to March 2007. Patient recruit-
ment had to be paused between 2003 and 2005 due to a
lack of resources. Detailed data were collected from initial
presentation at the ED until discharge, transfer or in-hos-
pital death. Patients with cardiogenic shock or end-stage
kidney disease (defined as serum creatinine levels of more
than 250 μmol/l in the first series and by haemodialysis
in the second period) were excluded, as these patients are
already known to be at a high risk of death [13, 14].
The study was carried out according to the principles of the
Declaration of Helsinki and approved by the local ethics
committee. Written informed consent was obtained from
all participants.
Adjudication of the AHF diagnosis
Two independent cardiologists reviewed all medical re-
cords pertaining to the patient (including B-type natriuretic
peptide (BNP) levels, chest X-ray, medical history, echo-
cardiography, cardiac catheterisation, pulmonary function
test, CT scan, right heart catheterisation, hospital course,
response to therapy, and autopsy data for those patients
who died in-hospital) from the time of ED presentation to
the results of the 90-day follow up. Cases of disagreement
were resolved in conjunction with a third cardiologist. For
the diagnosis and classification of AHF, the guidelines of
the European Society of Cardiology were interpreted as a
continuous variable to make best use of the information
provided by this test [1]. Absolute BNP values were adjus-
ted for the presence of both kidney disease and obesity to
maximise diagnostic accuracy [15].
Clinical evaluation and follow-up
Patients underwent an initial clinical assessment including
clinical history, a physical examination, an electrocardio-
gram, pulse oximetry, blood tests including B-type natriur-
etic peptide (BNP) measurement and a chest X-ray. Echo-
cardiography and pulmonary function tests were performed
according to the treating physician. Patients were contacted
for follow-up via telephone by trained researchers at 90,
180 and 360 days after discharge. Regarding mortality data,
referring physicians were contacted or the administrative
database of respective hometowns were reviewed if neces-
sary. A one year follow-up was completed in 100% of pa-
tients.
Risk model development
We performed CART analyses, as a multivariate statistical
technique, to identify the best predictors of 1-year mortality
and develop a risk stratification model. The CART method
allows the construction of an easily interpretable decision
tree that can be applied in clinical practice. As a first step,
the CART model calculates parameters with cut-off points,
which differentiate optimally between the study groups.
These cut-offs split the data into constituent groups. In a
second step, parameters are calculated, which offer the best
further differentiation between the subgroups. Thereby a
tree is created, whose branches are the various groups and
subgroups. The CART analysis stops branching until no
further significant splits are found or the subgroups become
too small. In a final step, the results are displayed in a bin-
ary structure, which is pruned as necessary [16, 17].
A total of 38 potential clinical and laboratory variables
of interest, inclusive of BNP and NT-pro BNP, were ad-
apted in the CART analysis. The variables were collected
from 150 registered variables in the cohort. The selection
of variables was carried out on the one hand by clinical
importance and on the other hand by risk factors, which
had already been identified in previous published studies
[18]. Based on the detected predictors for 1-year mortality,
patients were classified into risk groups. From these risk
groups a regression tree was developed and differences
regarding 1-year outcome were analysed. The predictive
value of this model was then assessed by determination
of hazard ratio (HR) and 95% confidence intervals (CIs)
between all risk groups. Finally, the risk stratification tree
was internally validated by cross-validation.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD) or medians (with interquartile range) and
categorical variables as numbers and percentages. Com-
parisons between groups were made using the Student’s t-
test, Chi-square test, Mann-Whitney U Test, Wilcoxon test
and Kruskal-Wallis test as appropriate. Correlations among
continuous variables were assessed by the Spearman rank-
correlation coefficient. In the 2-sided test, a p-value <0.05
was regarded as significant. To determine the best cut-
off of clinical variables in risk groups, CART analyses
were applied. The predictive value of this model regarding
1-year mortality was checked by the application of mortal-
ity HR and 95% CIs between all risk groups. Kaplan-Mei-
er analysis cumulative survival curves, in which patients
were divided into risk groups, were compared by the log-
rank test or χ² analysis. The likelihood-based 95%-confid-
ence set for age and urea-threshold was used for the intern-
al validation. All statistical analyses were performed using
SPSS/PC Version 15.0 (SPSS Inc, Chicago, IL).
Results
Patient’s demographics and characteristics
The baseline characteristics of the 610 patients presenting
with AHF are described in table 1. Overall, the mean age
was 82 years, and 46% of patients were women. A history
of hypertension was present in 71% of patients, chronic
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kidney disease in 39% and chronic obstructive pulmonary
disease in 25%. Diuretics (82%) were the most common
oral chronic medication recorded at the time of presenta-
Figure 1
Risk stratification algorithm of AHF patients regarding 1-year
mortality. Risk groups: high risk group (BUN >27.5 mg/dl and age
>86 years), intermediate risk group (BUN >27.5 mg/dl and age ≤86
years) and low risk group (BUN ≤27.5 mg/dl); each node is based
on available data from patients presenting to the ED.
Figure 2
Mortality in patients with AHFD over time according to risk groups:
high risk group (BUN >27.5 mg/dl and age >86 years), intermediate
risk group (BUN >27.5 mg/dl and age ≤86 years) and low risk group
(BUN ≤27.5 mg/dl).
Figure 3
Kaplan-Meier curves demonstrating cumulative survival in patients
with AHF over time according to risk groups: high risk group (BUN
>27.5 mg/dl and age >86 years), intermediate risk group (BUN
>27.5 mg/dl and age ≤86 years) and low risk group (BUN ≤27.5 mg/
dl); p <0.001 by log-rank.
tion to the ED, followed by inhibitors of renin-angiotensin-
aldosterone-system (angiotensin converting enzyme inhib-
itors and/or angiotensin receptor blocker) (76%), and beta-
blockers (61%). At 360 days, all-cause mortality was 33%.
Survivors differed from non-survivors in several baseline
characteristics including lower age, lower prevalence of
chronic kidney disease, higher systolic and diastolic blood
pressure, and several laboratory values. Plasma levels of
blood urea nitrogen (BUN) on admission were significantly
lower in survivors than in non- survivors. The same finding
was observed for serum creatinine, BNP and NT-pro BNP
(all p <0.01) (table 1).
Risk group stratification
For 1-year mortality in AHF patients, 38 clinical variables
were evaluated (table 2). The median length of follow-
up was 380 days. In the study cohort, 100% of subjects
had complete data and were included in the analysis. BUN
and age could be identified by CART analysis as the most
important risk relevant parameters, while BUN was the
strongest predictor. Patients were categorised according to
three risk groups: high risk group (BUN >27.5 mg/dl and
age >86 years), intermediate risk group (BUN >27.5 mg/
dl and age ≤86 years) and low risk group (BUN ≤27.5 mg/
dl) (fig. 1). A total of 55% of the cohort could be strati-
fied to low risk, while 29% were in the intermediate group
and 17% were in the high risk group. In table 3, all pa-
tients’ demographics and characteristics for each risk group
are summarised. Compared to low risk patients, a history of
chronic kidney disease was more common in the interme-
diate risk and high risk patient groups (p <0.01). The mean
systolic and diastolic blood pressure was significant lower
in the high risk group (p <0.01). In addition, mean values
of in-hospital stay increased by the level of risk group (high
risk: 18 ± 13; intermediate risk: 15 ± 11 and low risk: 13 ±
12 days; p <0.01).
Prediction of long-term outcome in risk groups
The CART tree with 1-year mortality data of each subgroup
is depicted in figure 1. Figure 2 illustrates an increase in
mortality according to risk group and the time interval after
hospital presentation. The figure clarifies that BUN and
age, as predictors of long-term outcome, are also suitably
applicable for risk assessment regarding in-hospital mortal-
ity, mortality at 30 days and mortality at 90 days.
The Kaplan-Meier analysis according to the risk groups at
presentation demonstrated lower one-year mortality in low
risk (22%) and intermediate risk groups (37%) compared
to the high risk group (63%) (Log-rank test p <0.001; fig-
ure 3). The HR regarding 1-year mortality between the high
and low risk groups was 1.9 (95% CI, 1.7–2.2), between
the high and intermediate risk groups it was 2 (95% CI,
1.5–2.7), and between the intermediate and low risk groups
it was 1.7 (95% CI, 1.3–2.3), with statistically significant
differences between all risk groups (p <0.001; table 4). We
used cross-validation to internally validate the results. The
likelihood-based 95%-confidence set for the age- and the
urea-threshold is contained in the rectangular set defined
by 25 mg/dl ≤ urea threshold ≤30.6 mg/dl and 76 years ≤
age threshold ≤96 years. Rehospitalisation for acute heart
failure was analysed as a secondary endpoint. Among the
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risk-groups, patients did not differ significantly in terms
of rehospitalisation due to heart failure (high-risk: 16% vs.
intermediate-risk: 26% vs. low-risk: 11%, p = 0.6).
Discussion
Early, rapid and accurate estimation of mortality risk in
AHF patients is an unmet clinical need. We report five ma-
jor findings from a large cohort of unselected AHF pa-
tients.
First, mortality was progressive over the whole period of
360 days and was very high at 1-year (33%). Only a minor-
ity (8%) of AHF patients died during the initial hospital-
isation. Secondly, CART analysis identified two simple and
universally available variables as the most powerful pre-
dictors of death. BUN and age were the strongest predict-
ors regarding 1-year mortality. It is interesting to note, that
these simple variables even outperformed novel biomark-
ers including BNP and NT-pro BNP [19–21]. Thirdly, the
definition of AHF patients at low, intermediate and high
risk can performed by BUN and age even as early as at
presentation to the ED. Fourth, this risk stratification al-
gorithm developed for 1-year mortality is also well suited
for the distribution of AHF patients into low, intermediate
and high risk regarding mortality in-hospital, at 30 days
and at 90 days. Fifth, our CART analysis extends recent
findings from ADHERE that BUN is not only the most
powerful predictor of in-hospital death but also of death
within 1 year.
These findings are of prime clinical pertinence, as predict-
ors regarding long-term outcome are poorly defined. Sever-
al prior studies have already demonstrated high mortality
Table 1: Demographic and clinical characteristics of all AHF patients.
¹= Paroxysmal nocturnal dyspnea, ² B-type natriuretic peptide, ³ N-terminal pro-B-type natriuretic peptide; Data are presented as median (interquartile range), number of
patients (%) or mean ± SD. *positive troponin T ≥0.04 ng/ml.
All AHF patients Non-survivors Survivors p-values
Total number of patients, n (%) 610 (100) 201 (33) 409 (67)
Age (year), median (IQR) 82 (75–88) 86 (79–89) 80 (73–86) <0.01
Female, n (%) 280 (46) 91 (45) 189 (46) 0.96
Arterial hypertension 430 (71) 135 (67) 295 (72) 0.64
Chronic obstructive pulmonary disease 154 (25) 58 (29) 96 (24) 0.31
Diabetes mellitus 180 (30) 56 (28) 124 (30) 0.71
Chronic kidney disease 243 (39) 108 (54) 135 (33) <0.01
Neoplastic disease 111 (18) 46 (23) 65 (16) 0.10
Medical history, n (%)
Stroke 174 (29) 67 (33) 107 (26) 0.20
Diuretics 475 (82) 151 (75) 261 (64) 0.25
Betablockers 357 (61) 99 (49) 202 (49) 0.95
Nitrates 201 (35) 46 (23) 80 (20) 0.51
ACE-Inhibitors/angiotensin receptor blockers 440 (76) 106 (53) 234 (57) 0.63
Digitalis 51 (9) 26 (13) 28 (7) 0.04
Aspirin 233 (40) 82 (41) 167 (41) 0.94
Calcium channel blockers 112 (19) 37 (18) 85 (21) 0.65
Long term medication use, n (%)
Anticoagulation 256 (44) 73 (36) 135 (33) 0.63
Dyspnea
NYHA I-II 53 (9) 12 (6) 41 (10) 0.17
NYHA III 294 (48) 81 (40) 213 (52) 0.12
NYHA IV 261(43) 108 (54) 153 (37) 0.02
Weight gain 149 (24) 52 (26) 97 (24) 0.72
Orthopnoe/PND¹ 332 (54) 106 (53) 226 (55) 0.81
Chest pain 213 (35) 65 (32) 148 (36) 0.57
Clinical symptoms, n (%)
Coughing 297 (49) 101 (50) 196 (48) 0.81
Elevated jugular venous pressure 202 (33) 80 (40) 122 (30) 0.10
Hepatojugular reflux 144 (24) 57 (28) 87 (21) 0.16
Rales 378 (62) 129 (64) 249 (61) 0.76
Clinical signs, n (%)
Peripheral oedema 319 (52) 112 (56) 207 (51) 0.56
Systolic blood pressure (mm Hg) 139
(122–162)
131
(114–156)
141
(125–166)
<0.01
Diastolic blood pressure (mm Hg) 85 (71–98) 80 (68–94) 86 (68–94) <0.01
Heart rate (beats per minute) 91 (74–111) 92 (75–108) 91 (74–111) 0.51
Vital status, median (IQR)
Oxygen saturation (%) 96 (92–98) 95 (90–98) 96 (93–98) <0.01
Blood urea nitrogen (mg/dl) 25.8 (18.2–41.3) 33.4 (22.5–50.5) 23 (16.8–36.5) <0.01
Creatinine (µmol/l) 106 (80–147) 125 (91–171) 100 (78–139) <0.01
Sodium (mmol/L) 138 (135–140) 138 (134–140) 138 (136–140) 0.19
Haemoglobin (g/l) 129 (114–143) 123 (111–140) 131 (116–145) <0.01
BNP² (pg/ml) 843 (445–1300) 1300 (635–1893) 741 (401–1300) <0.01
Pro-NT- BNP³ (pg/ml) 5966 (2177–13935) 13246 (5055–20851) 4165 (1845–9310) <0.01
Laboratory values, median (IQR)
Positive troponin T*, n (%) 255 (42) 112 (56) 143 (35) <0.01
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in patients with AHF after hospital discharge. The all-cause
mortality risk after hospitalisation has been reported to be
as high as 11% at 30 days and 40–50% at one year [11, 22].
Furthermore, early risk stratification might help to specific-
ally tailor medical therapies to the need of the individual
patient. This of course is of particular importance in emer-
gency medical practice. However, risk stratification has not
been integrated into the scenario of AHF because of differ-
ences in the clinical decompensated patients and due to the
complexity of risk models [23].
Renal function is an important determination of clinical
outcomes in cardiovascular disease [24, 25]. Patients with
AHF have a reduction of renal perfusion pressure and an
increase in water und urea reabsorption within hours and
days. BUN reflects the acute change in renal perfusion, so-
dium and water retention and neurohormonal activation. In
contrast, serum creatinine and creatinine-clearance are ac-
curate measures of renal function under stable conditions
[26]. Elevated BUN, as a better prognostic marker, may re-
flect the current worsening of the heart failure state in AHF
patients [27, 28]. Furthermore, older age was independ-
ently associated with 1-year mortality risk. The increased
risk of mortality in older patients with AHF has been ob-
served in previous HF studies [29, 30]. Manifestation of
AHF is apparently very frequent in the last year of life and
mainly in patients above 80 years of age. Risk stratification
may help in the earlier identification of patients hospital-
ised because of AHF for whom a hospice is an appropriate
care option and could provide a better quality of life [31,
32].
Our findings confirm and extend data from studies includ-
ing selected patients with severe AHF, in recent random-
ised studies such as EFFECT and OPTIME-CHF, in that
age and renal dysfunction are powerful predictors of long-
term mortality [12, 13]. Both demonstrated the prognostic
importance of an increase in BUN and older age as signific-
ant and independent predictors of death. Additional para-
meters have been correlated with mortality in AHF patients
including gender, aetiology and history of heart failure,
lower systolic blood pressure, comorbid conditions, serum
Table 2: Variables tested for their predictive potential for 1-year mortality.
¹ = paroxysmal nocturnal dyspnea, ² B-type natriuretic peptide, ³ N-terminal pro-B-type natriuretic peptide; Data are presented as median (interquartile range), number of
patients (%) or mean ± SD. Definition of risk groups: high risk group (BUN >27.5 mg/dl and age >86 years), intermediate risk group (BUN <27.5 mg/dl and age ≤86 years)
and low risk group (BUN ≤27.5 mg/dl). *Positive troponin T ≥0.04 ng/ml
Age
Gender
Systolic blood pressure
Diastolic blood Pressure
Heart rate
Elevated jugular venous pressure
Hepatojugular reflux
Pulmonary rales
Peripheral oedema
Dyspnea New York Heart Association (NYHA) state
Weight gain
Orthopnoe / paroxysmal nocturnal dyspnea
Chest pain
History of coronary artery disease
History of arterial hypertension
History of chronic renal insufficiency
History of chronic heart failure
Demographic and baseline clinical characteristics
History of diabetes
Diuretics
Betablockers
Nitrates
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers
Digitalis
Amiodaron
Aspirin
Calcium channel blockers
Chronic medication
Anticoagulation
Sodium
Potassium
Haemoglobin
Albumin
Creatinine
Blood urea nitrogen
Uric acid
C-reactive protein
B-type natriuretic peptide
N-terminal pro-B-type natriuretic peptide
Laboratory data
Positive Troponin (≥0.04 ng/ml)
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sodium and biomarkers, such as BNP, NT-proBNP and tro-
ponin I and T [8]. However, thus far risk models have been
complex issues and possessed limited clinical applicability.
The CART regression tree is a simple method for risk strat-
ification that is relatively easy to apply at the bedside.
Based on this schema the mortality risk can be estimated
with patient’s characteristics and laboratory parameters at
presentation to the ED.
Recently, ADHERE patient records were used to develop
a risk stratification tree, based on CART analysis for in-
Table 3: Demographic and clinical characteristics of risk groups.
High risk Intermediate risk Low risk p- values
Total number of patients, n (%) 103 (17) 174 (28.5) 333 (54.5)
Age (years), median (IQR) 91 (88–94) 79 (74–84) 81 (73–87) <0.001
Female, n (%) 52 (51) 39 (40) 159 (48) 0.38
Chronic heart failure 36 (35) 66 (57) 75 (23) 0.02
Coronary artery disease 64 (62) 101 (58) 163 (49) 0.15
Arterial hypertension 74 (72) 136 (78) 220(66) 0.43
Chronic obstructive pulmonary disease 23 (22) 50 (29) 81 (24) 0.99
Asthma bronchiale 1 (1) 5 (3) 8 (2) 0.55
Diabetes mellitus 22 (21) 79 (45) 79 (24) 0.34
Chronic kidney disease 70 (68) 125 (72) 48 (14) <0.01
Neoplastic disease 20 (19) 35 (20) 56 (17) 0.39
Medical history, n (%)
Stroke 32 (31) 66 (38) 76 (23) 0.06
Diuretics 86 (84) 146 (84) 180 (54) <0.01
Betablockers 49 (48) 115 (66) 137 (41) 0.11
Nitrates 29 (28) 40 (23) 57 (17) 0.04
ACE-Inhibitors / angiotensin receptor blockers 63 (61) 106 (61) 171 (51) 0.25
Digitalis 14 (14) 19 (11) 21 (6) 0.02
Amiodaron 6 (6) 27 (16) 28 (8) 0.87
Aspirin 52 (51) 68 (39) 129 (39) 0.24
Calcium channel blockers 16 (16) 46 (26) 60 (18) 0.85
Medication discharge, n (%)
Anticoagulation 31 (30) 65 (37) 112 (34) 0.84
Dyspnea <0.01
NYHA II 8 (8) 10 (6) 35 (11) 0.22
NYHA III 48 (47) 83 (48) 163 (49) 0.79
NYHA IV 47 (46) 81 (47) 133 (40) 0.40
Weight gain 24 (23) 63 (36) 62 (19) 0.08
Orthopnoe/PND¹ 49 (48) 107 (62) 176 (53) 0.91
Chest pain 36 (35) 62 (36) 115 (35) 0.92
Clinical symptoms, n (%)
Coughing 46 (45) 78 (45) 173 (52) 0.34
Elevated jugular venous pressure 52 (51) 58 (33) 92 (28) <0.01
Hepatojugular reflux 32 (31) 42 (24) 70 (21) 0.11
Rales 73 (71) 105 (60) 200 (60) 0.41
Clinical signs, n (%)
Peripheral oedema 64 (62) 110 (63) 145 (44) 0.02
Blood pressure (mm Hg)
Systolic 131 (112–158) 135 (112–162) 142 (127–163) <0.01
Diastolic 80 (67–90) 80 (68–93) 90 (76–102) <0.01
Heart rate (beats per minute) 87 (71–104) 89 (69–104) 96 (79–115) 0.03
Vital status, median (IQR)
Oxygen saturation (%) 96 (92–98) 96 (90–99) 96 (93–98) 0.89
Sodium (mmol/l) 138 (136–140) 138 (135–140) 138 (153–140) 0.19
Haemoglobin (g/l) 121 (111–134) 122 (107–137) 135 (121–147) <0.01
Creatinine (μmol/l) 152 (120–210) 143 (117–173) 84 (69–103) <0.01
BNP² (pg/ml) 1160 (602–1655) 985 (601–1492) 689 (357–1300) <0.01
Pro-NT- BNP³ (pg/ml) 11941 (7389–18644) 10285 (2799–25623) 3678 (1687–7822) <0.01
Laboratory values, median (IQR)
Positive troponin*, n (%) 61 (59) 88 (51) 106 (32) <0.01
Length of stay (days) mean (±SD) Total hospital 18 ± 13 15 ± 11 13 ± 12 <0.01
Table 4: Cox regression analysis with corresponding HR (95% CI) of all risk groups.
Long-term mortality between risk groups
Risk group analysis HR (95% CI) p-values
Intermediate risk 2 (1.5–2.7) <0.001High risk vs.
Low risk 1.9 (1.65–2.21) <0.001
Intermediate risk vs. Low risk 1.73 (1.3–2.3) <0.001
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hospital mortality. Of the 39 variables evaluated, the CART
method identified the following three variables as predict-
ors of mortality: BUN levels of ≥43 mg/dL (15 mmol/L),
systolic blood pressure at a discrimination level of less than
115 mm Hg and a serum creatinine level of >2.75 mg/
dL (243.1 µmol/L) at admission. This analysis also found
BUN to be the strongest predictor of in-hospital mortality.
Our findings highlight that some elements of the ADHERE
algorithm may not apply globally due to the restricted
transferability of the United States health care system. This
is important because some other trials have already demon-
strated that there are huge variations in mortality among
countries with differences in health care structure, cultural
background, and economic strength [33, 34]. One of the
differences is the aetiology of decompensation. The ma-
jority of American patients hospitalised with AHF have
evidence of systemic hypertension on admission [35]. As
demonstrated by many descriptive studies, the aetiology of
known heart failure in European patients was ischemic in
most of the cases [36]. In addition, there are major dif-
ferences in the length of hospitalisation of AHF patients
in the United States and most of the rest of the world.
The duration of hospital stay for AHF is longer in Asia,
Europe, Australia, Canada, and South America compared
to the United States [13, 37, 38]. This might have implic-
ations on in-hospital mortality, therefore we determined
mortality at 360 days after hospital presentation. Finally,
the ADHERE analysis was based on the subset of AHF pa-
tients selected for admission, while we recruited all AHF
patients at presentation to the ED.
Limitations
Several limitations apply to this study. Firstly, all studies at-
tempting to use a clinical diagnosis as gold standards for a
syndrome have some limitations. Although the gold stand-
ard diagnosis was adjudicated by two independent car-
diologists, misclassification remains a possibility because
AHF is a clinical diagnosis and no gold standard exists. Se-
condly, we assessed all-cause mortality because classifica-
tion of death in clinical practice can sometimes be difficult
and unreliable [39]. Thirdly, data derived from a single-
centre study always need to be replicated in larger multi-
centre studies. The risk stratification particularly requires
an external validation and bedside experience. However,
our patient cohort was comparable to those examined in re-
cent multicentre studies. Finally, patients with terminal kid-
ney failure requiring dialysis were excluded from the ana-
lysis.
Conclusion
Our results suggest that standard measures available at the
time of hospital presentation can provide important inform-
ation for risk stratification in AHF. Based on BUN (as the
strongest predictor regarding long-term mortality) and age,
AHF patients can quickly and effectively be stratified to
low, intermediate or high risk. Application of these simple
values may help physicians as a bedside tool for a better
management of AHF patients.
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Figures (large format)
Figure 1
Risk Stratification Algorithm of AHF Patients regarding 1-year Mortality. Risk groups: High risk group (BUN >27.5 mg/dl and age >86 years),
intermediate risk group (BUN >27.5 mg/dl and age £86 years) and low risk group (BUN £27.5 mg/dl); each node is based on available data from
patients presenting to the ED.
Original article Swiss Med Wkly. 2011;141:w13259
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 9 of 10
Figure 2
Mortality in patients with ADHF over time according to risk groups: high risk (BUN ≤;27.5 mg/dl and age >86 years), intermediate risk (BUN
≤27.5 mg/dl and age £86 years) and low risk (BUN ≤27.5 mg/dl).
Figure 3
Kaplan-Meier curves demonstrating cumulative survival in patients with ADHF over time according to risk groups: 1) high risk (BUN ≤;27.5 mg/dl
and age >86 years), 2) intermediate risk (BUN ≤27.5 mg/dl and age £86 years) and 3) low risk (BUN ≤;27.5 mg/dl); p <0.001 by log-rank.
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